Novel diagnostic PCR assay for Burkholderia cenocepacia epidemic strain ST32 and its utility in monitoring infection in cystic fibrosis patients  by Dedeckova, Klara et al.
www.elsevier.com/locate/jcf
Journal of Cystic Fibrosis 12 (2013) 475–481Original Article
Novel diagnostic PCR assay for Burkholderia cenocepacia epidemic strain
ST32 and its utility in monitoring infection in cystic ﬁbrosis patients
Klara Dedeckova a, c, Lucie Kalferstova a, c, Hynek Strnad b, Jolana Vavrova a, Pavel Drevinek a, c,⁎
a Department of Medical Microbiology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84, Prague 5, 150 06, Czech Republic
b Department of Genomics and Bioinformatics, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Videnska 1083, Prague 4, 142 20,
Czech Republic
c Department of Pediatrics, 2nd Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84, Prague 5, 150 06, Czech Republic
Received 15 October 2012; received in revised form 30 November 2012; accepted 10 December 2012
Available online 11 January 2013Abstract
Background: A highly transmissible Burkholderia cenocepacia sequence type (ST) 32 strain caused a major outbreak at the Prague Cystic Fibrosis
(CF) Centre in the late 1990s and early 2000s. Because a large number of CF patients were affected by ST32, a rapid and easy-to-use diagnostic
tool for ST32 infection was urgently needed for the detection of new cases as well as for long-term surveillance. The present study sought to
identify unique DNA sequences within the ST32 genome to develop an ST32 strain-speciﬁc PCR assay.
Methods: Genomic subtractive hybridisation between B. cenocepacia ST32 and the closely related genome-sequenced strain B. cenocepacia ST28
identiﬁed a 325 bp long region that was absent in all but one Burkholderia strain, as demonstrated by our newly designed PCR.
Results: Out of 57 strains, only B. cenocepacia ST33 cross-reacted with ST32, resulting in a PCR speciﬁcity of 98.2%. This speciﬁcity was further
tested by various genotyping methods, which revealed the practical indistinguishibility of ST32 and ST33. The PCR sensitivity, checked on a panel
of 50 ST32 clinical isolates, was 100%. A closer examination of the ST32-speciﬁc sequence revealed no signiﬁcant homology apart from a
fragment of the ISBmu3 transposase.
Conclusions: This novel ST32-speciﬁc PCR assay allows the rapid and reliable detection of a globally distributed B. cenocepacia epidemic strain.
Its routine use is especially well suited to infection surveillance programs for CF populations with a high rate of ST32 infection. This PCR method
can also be used to detect ST33, a clonal variant of ST32.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Bacteria of the Burkholderia cepacia complex (Bcc) are
some of the most problematic lung pathogens in patients with
cystic fibrosis (CF) [1]. Bcc infections are associated with poor
prognosis, repeated hospital stays and, in up to 20% of cases,
fatal cepacia syndrome, which is characterised by septicaemia
and necrotising pneumonia [2].
B. cenocepaciawas historically the most common Bcc species
recovered from CF patients attending the Prague CF Centre, with⁎ Corresponding author at: Department of Medical Microbiology, 2nd Faculty o
Medicine, Charles University, V Uvalu 84, Prague 5, Czech Republic. Tel.: +420
2 2443 5350; fax: +420 2 2443 5352.
E-mail address: pavel.drevinek@Lfmotol.cuni.cz (P. Drevinek).
1569-1993/$ -see front matter © 2012 European Cystic Fibrosis Society. Pub
http://dx.doi.org/10.1016/j.jcf.2012.12.007flishedan infection rate of up to 30% in the early 2000s [3]. The strain
responsible for this Czech epidemic was identified by multilocus
sequence typing (MLST) [4] as sequence type 32 (ST32), and this
strain was also recognised as the cause of epidemic outbreaks in
other countries (France, Italy, the UK and Canada, as reviewed in
[5]). In 2001, the ST32 strain was found in nearly all Prague CF
patients who suffered from Bcc infection (93%; 52 out of 56
infected patients) [3]. The spread of the infection was eventually
stopped primarily as the result of a systematic infection
surveillance program implemented by the CF treatment centre.
The program included regular PCR-based detection of Bcc
bacteria directly from sputum isolated from each patient [6] and
strain identification of clinical isolates by genotyping techniques
including direct-sputum DNA based MLST [7] and randomby Elsevier B.V. All rights reserved.
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these detection and subsequent clinical management measures,
no new ST32-positive patients have been detected in the Prague
CF community since 2004 [3].
Bcc infection surveillance is demanding in terms of both
time and cost, especially when the MLST technique is used to
identify strains. Because of this, we sought to develop a simple,
inexpensive, but specific test for the rapid detection of ST32
that could replace the costly and time-consuming genotyping
techniques currently used to monitor ST32 infections. We
exploited a genomic subtractive hybridisation technique to find
ST32-specific DNA markers and subsequently designed a
strain-specific PCR assay. This strategy has already proven
useful for other CF pathogens, such as the Liverpool or
Midlands epidemic strains of Pseudomonas aeruginosa [9,10].
2. Methods
2.1. Bacterial strains
All strains used in this study were grown on tryptone soya
agar overnight at 37 °C. The strains used for subtractive
hybridisation, B. cenocepacia ST28 (J2315, LMG16656)
and B. cenocepacia ST32 (CCM7291, Czech Collection of
Microorganisms, 1232), were grown in Luria Bertani (LB)
broth overnight at 37 °C with shaking at 200 rpm. The ST32-
PCR specificity and sensitivity evaluations used 57 strains from
the Bcc group (Cardiff University strain collection, summarised
in Supplementary Table 1), 50 ST32 clinical isolates that were
recovered from 50 Prague CF patients and 16 non-Bcc strains
(Pseudomonas syringae CCM2868, Pseudomonas aeruginosa
Manchester epidemic strain C3652, Pseudomonas stutzeri
LMG11199, Pseudomonas pseudoalcaligenes LMG1225,
Pandoraea apista LMG16407, Pandoraea pnomenusa
LMG18087, Ralstonia pickettii LMG18088, Ralstonia insidiosa
LMG18101, Ralstonia mannitolilytica LMG18103, Pandoraea
pulmonicola LMG18106, Achromobacter xylosoxidans
LMG1863,Pandoraea sputorumLMG18819, Inquilinus limosus
LMG20952, Cupriavidus respiraculi LMG21510, Pseudomonas
putida LMG2257 and Stenotrophomonas maltophilia LMG958).
2.2. Construction of subtractive hybridisation libraries
Genomic subtractive hybridisation between B. cenocepacia
ST28 as a driver and B. cenocepacia 1232 as a tester was
performed using a PCR Select Bacterial Genome Subtraction
kit (Clontech) according to the manufacturer's instructions,
with several modifications. Briefly, 2 μg of tester and driver
DNA were digested with 15 U of RsaI enzyme in 200-μl
reaction volume for 5 h at 37 °C. The tester DNA was ligated
to two different adaptors in separate tubes by T4 DNA ligase
and allowed to undergo two rounds of hybridisation with a
driver at 73 °C [11]. Two sequential PCRs were carried out to
selectively amplify tester-specific DNAs. Both PCR rounds
were performed with reagents from the Advantage 2 PCR kit
(Clontech) according to the manufacturer's protocol, with the
following modifications: the total reaction volume was 20 μl,and the 1× Advantage 2 SA PCR buffer was used in the second
PCR. The products from the second round of PCR were
inserted into the pCR®II-TOPO® vector (Invitrogen). The
molar ratio of PCR:vector was 3:1. Ligated DNAs were
transformed into One Shot® Mach1™-T1R chemically com-
petent E. coli (Invitrogen). The transformed bacteria were
spread on low-salt LB medium with ampicillin, IPTG and
X-Gal (Invitrogen) for white/blue screening. White colonies
were picked into 150 μl of LB broth containing 50 μg/ml
ampicillin in 96-well microtiter plates and grown at 37 °C
overnight with shaking at 200 rpm. Inserts were amplified
using 0.5 μM M13 reverse primer and 0.5 μM M13(-20)
forward primer (Invitrogen) in 15 μl master mix (AmpliTaq
Gold kit) containing 1× PCR Gold Buffer, 2.5 mM MgCl2,
0.2 mM (each) dNTP and 0.5 U of AmpliTaq Gold DNA
Polymerase. The PCR thermal conditions consisted of an initial
denaturation at 95 °C for 10 min followed by 40 cycles at
95 °C for 15 s, 55 °C for 30 s, and 72 °C for 90 s and a final
extension at 72 °C for 2 min. Insert size was estimated via 2%
(wt/vol) agarose gel electrophoresis.
2.3. DNA sequencing
Amplified PCR products were purified using MagneSil Para-
magnetic Particles (Biomek 3000, Beckman Coulter). Sequence
reactions were performed using the BigDye Terminator v3.1 Kit
(Life Technologies) and primers SP6 or T7 (Invitrogen). The
nucleotide sequences of the inserts were determined by auto-
mated DNA sequencing (ABI 3130xl, Biotechnology Center).
Tester-specific sequences were further analysed by using
BLASTN and BLASTX searches of the National Center for
Biotechnology Information (NCBI) Database, available online,
and a BLASTX search of the Burkholderia Genome Database
(BGD), available at http://www.burkholderia.com. The BLAST
analysis was performed in August 2011.
2.4. B. cenocepacia ST32 strain-specific PCR assay
Primers were designed using the Primer Design Assistant
(http://dbb.nhri.org.tw/primer/index.html). The oligonucleotide
primer sequences used in the study are listed in Supplementary
Table 1. PCR was carried out in a duplicate in a total volume of
20 μl with 1 μl bacterial DNA extracted with 5% Chelex (200–
400 mesh, BioRad) and reagents from the Taq PCR Core kit
(Qiagen): 1× PCR buffer, 1× Q-solution, 0.2 mM (each) dNTP,
0.5 μM 1B_325F forward primer (CCGTTGCATACCGTCCG
AAATG) and 1B_325R reverse primer (CGCAGCAATGCA
CACGAGAAAG) and 0.75 U Taq polymerase. The PCR was run
on a Labcycler SensoQuest thermal cycler (Schoeller Instruments)
with initial denaturation for 5 min at 94 °C followed by 30 cycles
of 94 °C for 30 s, 60 °C for 45 s and 72 °C for 2 min. The PCR
products were separated on 2% (wt/vol) agarose gel with 1× TBE
buffer at 6 V/cm.
To evaluate the specificity of the PCR, we used: (i) 57 different
Bcc strains of defined sequence type and (ii) 16 non-Bcc bacterial
strains that represent closely related species that are found in CF
lungs. To determine the sensitivity of the PCR, (iii) 50 clinical
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were used. The detection limit was determined by serial dilutions
of DNA that was extracted from a stock culture of known CFU/ml
as published in [12].
2.5. B. cenocepacia genotyping methods
MLST, macrorestriction typing followed by pulsed-field gel
electrophoresis (PFGE) and RAPD methods were used to geno-
type Bcc bacteria. MLST was performed as described previously
[4], with modified primers as published in [13]. PFGE was
carried out as described previously [14]. The PCR-based RAPD
genotyping technique was performed according to a previously
described protocol [15]. The results from both methods were
analysed by Pearson correlation in BioNumerics software
(Applied Maths, Belgium).
3. Results
3.1. Genomic subtractive hybridisation to reveal ST32-specific
DNA
To identify targets suitable for ST32-specific PCR assay, we
performed genomic subtractive hybridisation (GSH) between
the strain in question (a tester) and the closely related strain
ST28 (a driver), for which a full genome sequence is available
[16]. After cloning the subtracted DNA into E. coli cells, we
recovered 58 different sequences of 62 to 756 bp in length from
111 randomly picked colonies (18 of 58 sequences were
repeated 2 to 4×). Based on BLAST results retrieved from the
NCBI sequence database (U.S. National Library of Medicine)
and the Burkholderia genome web page [17] the sequences
were split into following categories, defined by their presence
or absence in other Burkholderia species (Supplementary
Table 2): (i) high nucleotide sequence similarity with the driver
B. cenocepacia ST28 (N80% identity along the whole length of
the cloned insert): 8 sequences; (ii) low nucleotide or amino
acid sequence similarity with B. cenocepacia ST28 (b50%): 4
sequences; (iii) sequence similarity to any other publicly
available Bcc sequence: 24 sequences; (iv) sequence similarity
to sequences from Burkholderia spp. that are not members of
the Bcc group: 14 sequences, and (v) no sequence similarity to
any other available Burkholderia sequence: 8 sequences.
The data indicated that the ST32 strain possessed sequences
absent not only in the comparative strain ST28 but also in all
other Bcc bacteria that have been sequenced to date. These
putative ST32-specific sequences became the primary candi-
dates for strain-specific PCR assay.
3.2. B. cenocepacia ST32 strain-specific PCR assay
Seven sequences with regions lacking significant homology to
any Bcc were selected as targets for the novel PCR (Table 1).
PCR primers were developed for each sequence (see Supple-
mentary Table 1 for primer sequences specific to each target) and
tested for specificity on a panel of 57 Bcc strains that spanned the
current diversity within the Bcc. To maximise the efficacy oftesting, the initial screen for PCR specificity was carried out with
close relatives to ST32 and other known B. cenocepacia epidemic
strains (ST33, ST210, ST211, ST276, ST234, ST31 and ST28). If
satisfactory results with no or sparse cross-reactivity were
retrieved, the pool of tested strains was extended (the PCR
results of all primer-template combinations are summarised in
Supplementary Table 1). Only 4 PCRs displayed sufficient ST32
specificity, and they were also all positive for strain ST33 (for
further details see below).
Sensitivity testing of these 4 PCRs was performed on 50
clinical isolates of ST32 (as confirmed before by MLST). Two
PCR assays failed to amplify one sample each; these failures
were interpreted as false negatives. A 100% sensitivity was
achieved by other two PCRs that worked for sequences 4G and
1B (target 4G-t was 260 bp long and 1B-t was 325 bp).
Ultimately, the 1B variant (Table 1) was selected for further use
because it produced a longer PCR product and was thus more
convenient for band visualisation on a gel electrophoresis.
The threshold of the novel PCR assay, if applied to the
detection of bacterial DNA in distilled water, was found to be
4·103 CFU/ml. A final step in testing for specificity was to rule
out reactivity with other bacteria that might be present in CF
sputum. No reactivity was observed for any of the 16 non-Bcc
species tested.
3.3. Genotyping to assess the relatedness between B. cenocepacia
ST32 and ST33
The specificity of the novel PCR assay was below 100%
because of its cross-reactivity with B. cenocepacia ST33. To
evaluate this putative lack of specificity and to check how
genetically close ST32 and ST33 are to each other, three
different genotyping techniques were applied: MLST, PFGE
and RAPD. MLST showed that the strains were single locus
variants that differed only by one single nucleotide polymor-
phism within a 2773 bp sequence concatenated from all seven
MLST alleles. The PFGE experiment performed on ST33,
ST28 and ST32 isolates showed no clear distinction between
ST33 and ST32 (Fig. 1). Similarly, RAPD could not separate
ST32 from ST33; on the contrary, their fingerprints similarity
values were greater than 92% (Fig. 2A and B). Thus,
genotyping clustered the two strains into a single clone despite
their putative split, introduced by MLST.
3.4. Characteristics of the target sequence used for strain-
specific PCR assay
To further analyse and identify the position of the target
sequence within the ST32 genome, we utilised preliminary data
available from on-going whole-genome sequencing of the
ST32 strain (H.S., unpublished data). A 526 bp long sequence
obtained by subtractive hybridisation (sequence 1B, Table 1)
was found to be unique to the ST32 genome and to belong to a
1149 bp region that was not present in the ST28 genome
(Fig. 3). This 1149 bp fragment was composed of: (A) a 323 bp
long sequence that was homologous to part of an ISBmu3
transposase, (B) a 65 bp sequence without any significant hits,
Table 1
Clone inserts used as potential targets for ST32-PCR.
Sequences are grouped by their level of identity to Burkholderia organisms as indicated in “Identity per full length of cloned insert” (see Results for further details).
The sequences were analysed by BLASTN and BLASTX at both the NCBI and BGD sequence repositories. Specific BLAST tools and database sources are indicated
in “BLAST search” only if different results were retrieved. NSH, no significant hits. * The variant selected for ST32-PCR.
Group ID Length
(bp)
BLAST
search
Best match:
organism
Best match:
cds or protein
BLAST
identity
Identity per full length
of cloned insert
E-value
(ii) 5B 583 B. cenocepacia J2315 Potassium-transporting ATPase A chain 218/218 (100%) 37% (bp) 7e−109
(iii) 7D 696 NCBI BLASTN NSH
NCBI BLASTX NSH
BGD BLASTX Burkholderia 383 TetR family transcriptional regulator 99/135 (73%) 43% (aa) 5e−52
(iv) 5H 264 NCBI BLASTN NSH
NCBI BLASTX Cellvibrio sp. BR Hypothetical protein 79/87 (91%) 90% (aa) 3e−48
BGD BLASTX B. thailandensis_E264 Phospholipase C 29/77 (37%) 33% (aa) 0.26
4 G 269 NCBI BLASTN NSH
NCBI BLASTX B. xenovorans LB400 Putative integrase/recombinase 18/27 (67%) 20% (aa) 0.020
BGD BLASTX B. xenovorans LB400 Integrase/recombinase 18/27 (66%) 20% (aa) 0.001
1B* 526 NCBI BLASTN NSH
NCBI BLASTX B. phymatum Hypothetical protein 31/56 (55%) 18% (aa) 2e−10
BGD BLASTX B. phymatum Hypothetical protein 31/56 (55%) 18% (aa) 2e−10
2E 427 NCBI BLASTN NSH
NCBI BLASTX Roseomonas cervicalis Hypothetical protein 21/45 (47%) 15% (aa) 0.11
BGD BLASTX B. pseudomallei Flavoprotein reductase 19/58 (32%) 13% (aa) 0.18
(v) 8E 303 NSH
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through GSH, 325 bp of which served as the PCR target 1B-t (the
1B sequence contained no cds or ncRNA and was identified in
one copy in the ST32 genome); and (D) a 235 bp long fragment
with a homology to fragments of hypothetical proteins. The DNA
flanking the 1149 bp area included genes that were present in the
ST28 genome: an incomplete cds for the type VI secretion system
Vgr family protein BCAL1165 (1746 bp out of 2508 bp;
truncated by the ST32-specific DNA fragment) and a complete
hypothetical gene BCAL0333 on the other side of the ST32-
specific region.
3.5. ST32-PCR assay as part of a laboratory protocol for the
surveillance of Bcc infections
The workflow for strain identification currently in use at the
Prague CF centre is depicted in Fig. 4. As indicated, all Bcc-
positive samples are examined at the strain level. By including45
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Fig. 1. PFGE of SpeI-digested B. cenocepacia ST28, ST33 and ST32 genomes. The s
collection), BCC0961 (ST32; Cardiff University collection) and four different ST32the ST32 strain-specific PCR assay in the examination algorithm,
ST32 is identified rapidly without the need for more laborious
and expensive genotyping techniques. Samples that are defined
to be Bcc-positive but ST32-PCR negative are subjected to
MLST and/or RAPD analysis. In principle, MLST is primarily
indicated for strain identification in newly diagnosed cases of Bcc
infections, while the less expensive RAPD technique is per-
formed in chronically infected patients to check whether they are
still carrying the same strain or whether their strain has been
replaced with a new one. As a rule, patients with chronic infec-
tions are tested annually.
Because RAPD by its nature requires pure cultures, it cannot
be applied to samples in which Bcc bacteria were detected by
Bcc-specific recA PCR rather than by culture. Such samples,
which in most cases are positive in round 2 of the nested recA
PCR, must be examined by MLST which has been modified for
direct use on sputum samples [7]. Additionally, ST32-specific
PCR assay, which was designed as a single-round PCR, is not50
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Fig. 2. RAPD fingerprint profiles of B. cenocepacia ST28, ST33 and ST32. Profiles generated using A) RAPD primer 270 and B) RAPD primer 272 [8]. The strains
used were as follows: J2315 (ST28); BCC0560 (ST33; Cardiff University collection); BCC0961 (ST32; Cardiff University collection).
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are detectable only after two rounds of recA PCR.
Sputum samples were recovered from 18 chronically infected
patients during the first 10 months of the use of the updated
protocol for infection surveillance. Three of them were known
from the past to be harbouring ST32, while remaining 15 patients
were infected with other Bcc strains. ST32-PCR results were
100% concordant with infection status of 13 patients (in 5 cases,
the Bcc was detected in round 2 of the recA PCR which meant to
check strain identity with MLST). No case of new Bcc infection
occurred during this time period.
4. Discussion
In the present study, genomic subtractive hybridisation was
applied to identify sequences that are specific to the Czech
epidemic strain B. cenocepacia ST32 and not present in the
closely related strain B. cenocepacia ST28 (J2315), the genome
of which was completely sequenced and published [16]. By
obtaining DNA fragments with low or no sequence similarity to
ST28 or any other known Bcc sequences, we were able to easily
select several targets for strain-specific PCR assay. Ultimately,
novel PCR for rapid detection of ST32 strain targeted a 325 bp
long sequence (1B-t) that had been identified as part of 1149 bp
region. Although the function of this region is essentially
unknown, we can assume that it was introduced/formed by
several transposition events, as indicated by the presence of a
323 bp long sequence with homology to part of the ISBmu3-388 -65 +
ST28+ST32 ST32
Incomplete BCAL1165
A B
Fig. 3. Characteristics of the DNA region containing the target sequences for ST32-
strains. 1B-t: the PCR target. See Results for a description of parts A to D.transposase, presumably integrated into the BCAL1165 gene.
The whole ST32-specific region contains many gene fragments,
or pseudogenes, that show very weak homology to helicases
and integrases. Notably, and unexpectedly, the flanking genes
in the immediate vicinity of the region (i.e., the BCAL1165 and
BCAL0333 genes) are not syntenic with the ST28 genome.
The ST32-PCR method was tested on 57 different ST types
within the Bcc. Its specificity was calculated as 98.2% because
ST33 produced the same PCR result as ST32. This cross-
reactivity can be interpreted as a lack of PCR specificity, although
the extent to which these two sequence types should be con-
sidered separate entities is questionable; three different genotyping
methods demonstrated their practical indistinguishability.
PFGE SpeI digests did not distinguish one strain from another
because the pattern heterogeneity observed at the intra-strain
level (a phenomenon reported in ST32 by [14]) resulted in the
creation of a common cluster for both STs. The RAPD analysis
revealed no difference in their patterns, and historically, prior to
the introduction of the MLST scheme, both STs were considered
to represent a single RAPD cluster 01 simply because of their
identical fingerprints ([8]; E. Mahenthiralingam, A. Baldwin
unpublished data). These strains have different ST labels only
because of a single nucleotide polymorphism found in recA,
while the remaining 2772 nucleotides of all 7 alleles examined by
MLST were identical. Based on these data, we can presume that
these two STs were derived from a single clone that diversified
very recently (expressed as a point mutation in MLST analysis).
Thus, the ST32-ST33 cluster can be considered one clonal1 +526 +761
ST28+ST32specific sequence
BCAL0333
1B-t
C D
specific PCR assay. White: unique to ST32; grey: common to ST28 and ST32
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Fig. 4. Examination strategy for screening and monitoring Bcc infections at the Prague CF Centre. Flow charts applicable to A) new Bcc infections; B) chronic Bcc
infections. * If a previous isolate is not available, RAPD is performed for both isolates (the previous and the current one).
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contrast to the ST32 found in a single geographical location only
(Canada). Genotyping data and epidemiological context indicate
that distinction between ST33 and ST32 is unlikely to be relevant
or clinically meaningful. The ST32-PCR assay described here
can be therefore considered a suitable tool for the rapid detection
of this strain lineage with no concerns about false reactivity to any
other genetically or epidemiologically unrelated strain.
This novel ST32-PCR assay has been used in the routine Bcc
infection surveillance programme at the Prague CF Centre. Its
great advantages lie not only in the reduction of costs associated
with strain typing but also in the minimisation of the time needed
to confirm a new ST32 case. This has obvious important
consequences for timely patient separation and further improve-
ments in the efficacy of infection control policies.
The practicability of everyday use of any strain-specific PCR is
underlined especially in scenarios in which a substantial number
of the investigated isolates are likely to belong to a particular
strain. In the past, PCRs for several Bcc strains were developed to
facilitate the detection of epidemiologically important strains,
namely the cblA marker for the ET12 lineage [18], the BCESM
marker for B. cenocepacia epidemic strains of the recA IIIA group
[19], and the IS1363 marker for the ET12 and PHDC epidemic
strains [20]. Their practical use has been demonstrated extensive-
ly, for instance, IS1363 PCR was used to screen a large number of
B. cenocepacia isolates to identify European counterparts of the
American epidemic strain PHDC [21]. In analogous fashion, the
introduction of ST32-PCR assay was very welcome in the
screening of Bcc clinical isolates at the Prague CF centre, where
ST32 remains a predominant Bcc strain.5. Conclusions
In conclusion, we have developed an easy-to-use PCRmethod
that is able to detect epidemic B. cenocepacia ST32. We have
demonstrated the close relatedness between sequence types ST32
and ST33, which can be both detected by this novel PCR assay.
We also proposed an examination strategy algorithm for the
surveillance of Bcc infections in CF centres.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jcf.2012.12.007.
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